Faruqi and Faruqui, LLP Logo
Share this page

Zosano Pharma Corporation (ZSAN)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Zosano Pharma Corporation To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ:ZSAN).

The investigation focuses on whether the Company and its executives violated federal securities laws by making false statements regarding and/or failing to disclose the commercial viability of its main product, the osteoporosis drug program ZP-PTH, in connection with the Company’s January 27, 2015 Initial Public Offering (“IPO”).

Specifically, in January 2015, Zosano offered more than 6,500,000 shares of its common stock at $11.00 per share in connection with its IPO. Fifteen months later, however, Zosano common stock has declined and was trading at just $2.26 per share during intra-day trading on April 8, 2016 – a 79.5% drop from its IPO price.

Take Action

If you invested in Zosano stocks or options and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Zosano’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Zosano Pharma Corporation (ZSAN)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 04/08/2016

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.